Biotech and Pharmaceuticals Biotechnology

  • Déjà vu for biotechs

    CNBC's Meg Tirrell reports on the recent drop in biotechs and whether it is a threat to the overall market.

  • Be selective in biotech: Pro

    CNBC contributor Barbara Ryan of Clermont Partners, discusses whether biotech is a good place to be right now, and how investors

  • Biotech brawl: Bull vs. ...bull

    Eric Schmidt, Cowen & Co. biotech analyst, thinks biotech will continue to be a great business and will move higher. Insight, with Geoff Porges, Sanford Bernstein.

  • Who can beat the 'superbug'?

    A new antibiotic-resistant "superbug" may have contributed to the deaths of 2 patients at Ronald Reagan-UCLA Medical Center. What companies may be on track to combat the deadly virus, with CNBC's Meg Tirrell.

  • Statue of Genghis Khan

    New DNA evidence says significant chunks of humanity may carry genes from a few powerful men, including Genghis Khan.

  • US earnings: 'Tech to the rescue'

    Caterpillar and 3Ms' poor earnings performance "spooked investors", however tech and healthcare are expected to save the earnings season, says Christine Short, senior vice president at Estimize.

  • The rise and rise of biotech stocks?

    Biotech stocks in the U.S. have outperformed significantly over the last three years -- and this can continue, says Matthew Roden, executive director of biotechnology equity research at UBS AG.

  • Biopharma's challenges in 2015

    Biopharma executives at the J.P. Morgan Healthcare Conference talk about this year's biggest challenges.

  • I am a better person: Sam Waksal

    Sam Waksal, former Imclone Systems CEO, reveals how the ImClone scandal has impacted his life.

  • I'm not running the show: Sam Waksal

    CNBC's Meg Tirrell, and Sam Waksal, Kadmon founder & chairman, discusses his role in the company.

  • Sam Waksal's IPO biotech plans

    CNBC's Meg Tirrell, and Sam Waksal, Kadmon founder & chairman, discuss plans to take the biotech company public.

  • Biogen Idec beefs up pain pipeline

    Dr. George Scangos, Biogen Idec CEO, discusses new therapies in multiple sclerosis, Alzheimer's disease and pain.

  • 23andMe partners with big pharma

    Anne Wojcicki, co-founder and CEO of genetic-testing startup 23andMe, discusses the new deals with Pfizer and Genentech.

  • Celgene CEO: Creating a great future

    CNBC's Meg Tirrell speaks to Robert Hugin, Celgene chairman & CEO, about the company's ambitious long-term guidance and broad-based drug pipeline.

  • Analyzing Eli Lilly's drug pipeline

    CNBC's Meg Tirrell speaks to John Lechleiter, Eli Lilly CEO, about the strength and outlook for the health care sector, and what new drugs he's most excited about.

  • Stock moving information kept behind doors

    CNBC's Meg Tirrell provides insight to the debate over transparency from biotech companies. Biotech investor Brad Loncar, thinks this is just an awareness issue.

  • Cramer: This sector was up 33% last year

    The biotechs were one of the best performing sectors for 2014. Can it work wonders for 2015? Cramer gives his top players in the biotech space.

  • Biotech's strong pipeline

    A total of 71 biotech companies went public in 2014. Cowen Group President and Cowen & Company CEO Jeffrey Solomon, discusses the market sentiment toward the sector.

  • Will biotech bull run continue?

    Discussing the outlook on the pharmaceutical sector, including leaders like Gilead and Celgene, with Michael Yee, RBC Capital Markets biotech analyst.

  • Gilead pops, AbbVie drops

    Gilead Sciences is lifting the biotech sector higher in today's trade, reports CNBC's Meg Tirrell.